FDA’s CDER Is Fostering Use Of Artificial Intelligence In Drug Development

 
• By Brenda Sandburg

Center for Drug Evaluation and Research plans to issue a request for information this year to engage stakeholders on issues related to AI and machine learning. It received 175 AI/ML submissions in 2022, up from 14 in 2020.

AI medical
FDA is focusing on use of artificial intelligence and machine learning to enhance drug development • Source: Shutterstock

More from AI

More from Advanced Technologies